GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (FRA:RGO) » Definitions » Sale Of Investment

Regeneron Pharmaceuticals (FRA:RGO) Sale Of Investment : €13,590 Mil (TTM As of Sep. 2024)


View and export this data going back to 1990. Start your Free Trial

What is Regeneron Pharmaceuticals Sale Of Investment?

Regeneron Pharmaceuticals's sale of investment for the three months ended in Sep. 2024 was €3,837 Mil. It means Regeneron Pharmaceuticals gained €3,837 Mil from selling investments. Regeneron Pharmaceuticals's sale of investment for the trailing twelve months (TTM) ended in Sep. 2024 was €13,590 Mil.

Compared with last quarter (€3,767 Mil in Jun. 2024 ), Regeneron Pharmaceuticals gained more money from selling investments in Sep. 2024 (€3,837 Mil).


Regeneron Pharmaceuticals Sale Of Investment Historical Data

The historical data trend for Regeneron Pharmaceuticals's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Sale Of Investment Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,443.78 3,111.27 1,960.54 5,239.67 8,658.50

Regeneron Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,808.94 2,185.12 3,801.62 3,766.63 3,837.00

Regeneron Pharmaceuticals Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €13,590 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regeneron Pharmaceuticals Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals Business Description

Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines